Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roopal Thakkar

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Digestive Diseases and Sciences|July 16, 2016
Direct Costs in Patients with Celiac Disease in the USA: A Retrospective Claims AnalysisStefano Guandalini, Namita Tundia, Roopal Thakkar, et al.
Journal of Clinical Lipidology|February 5, 2011
Efficacy and safety of combination therapy with niacin extended-release and simvastatin versus atorvastatin in patients with dyslipidemia: The SUPREME StudyWilliam Insull, Jan N Basile, Anthony N Vo, et al.
Journal of Crohn'S & Colitis|May 31, 2014
Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's diseaseMamoru Watanabe, Toshifumi Hibi, Nael M Mostafa, et al.
Journal of Crohn'S & Colitis|March 23, 2013
Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trialsWilliam J Sandborn, Jean-Frederic Colombel, Julian Panés, et al.
Clinical Drug Investigation|March 24, 2009
Flushing ASsessment Tool (FAST): psychometric properties of a new measure assessing flushing symptoms and clinical impact of niacin therapyAriane K Kawata, Dennis A Revicki, Roopal Thakkar, et al.
Inflammatory Bowel Diseases|February 13, 2019
Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease: Results of the PYRAMID RegistryEdward V Loftus, Walter Reinisch, Remo Panaccione, et al.
European Journal of Heart Failure|January 23, 2009
Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVEAlexandre Mebazaa, Markku S Nieminen, Gerasimos S Filippatos, et al.
JAMA|May 3, 2007
Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized TrialAlexandre Mebazaa, Markku S Nieminen, Milton Packer, et al.
Journal of Gastroenterology|April 14, 2017
Erratum to: Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitisYasuo Suzuki, Satoshi Motoya, Hiroyuki Hanai, et al.
Journal of Gastroenterology|March 22, 2017
Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitisYasuo Suzuki, Satoshi Motoya, Hiroyuki Hanai, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Digestive Diseases and Sciences|July 16, 2016
Direct Costs in Patients with Celiac Disease in the USA: A Retrospective Claims AnalysisStefano Guandalini, Namita Tundia, Roopal Thakkar, et al.
Journal of Clinical Lipidology|February 5, 2011
Efficacy and safety of combination therapy with niacin extended-release and simvastatin versus atorvastatin in patients with dyslipidemia: The SUPREME StudyWilliam Insull, Jan N Basile, Anthony N Vo, et al.
Journal of Crohn'S & Colitis|May 31, 2014
Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's diseaseMamoru Watanabe, Toshifumi Hibi, Nael M Mostafa, et al.
Journal of Crohn'S & Colitis|March 23, 2013
Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trialsWilliam J Sandborn, Jean-Frederic Colombel, Julian Panés, et al.
Clinical Drug Investigation|March 24, 2009
Flushing ASsessment Tool (FAST): psychometric properties of a new measure assessing flushing symptoms and clinical impact of niacin therapyAriane K Kawata, Dennis A Revicki, Roopal Thakkar, et al.
Inflammatory Bowel Diseases|February 13, 2019
Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease: Results of the PYRAMID RegistryEdward V Loftus, Walter Reinisch, Remo Panaccione, et al.
European Journal of Heart Failure|January 23, 2009
Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVEAlexandre Mebazaa, Markku S Nieminen, Gerasimos S Filippatos, et al.
JAMA|May 3, 2007
Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized TrialAlexandre Mebazaa, Markku S Nieminen, Milton Packer, et al.
Journal of Gastroenterology|April 14, 2017
Erratum to: Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitisYasuo Suzuki, Satoshi Motoya, Hiroyuki Hanai, et al.
Journal of Gastroenterology|March 22, 2017
Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitisYasuo Suzuki, Satoshi Motoya, Hiroyuki Hanai, et al.
Pageof 2